EO4010

DRUG2 trials

Sponsors

Enterome

Conditions

Colorectal Cancer MetastaticPatients with unresectablepreviously treated locally advanced or metastatic colorectal carcinoma.

Phase 1

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

TerminatedNCT05589597

EnteromeColorectal Cancer Metastatic

Start: 2023-06-01End: 2025-05-30Updated: 2025-08-22

A global multicenter phase 1/2 trial of EO4010, a novel microbial-derived peptide therapeutic vaccine, in combination with nivolumab and/or bevacizumab, for treatment of patients with previously treated metastatic colorectal carcinoma (the "AUDREY" study).

CompletedCTIS2023-509509-62-00

EnteromePatients with unresectable, previously treated locally advanced or metastatic colorectal carcinoma.

Start: 2023-05-03End: 2025-05-29Target: 28Updated: 2025-06-11

Related Papers

Survival of patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal carcinoma (mCRC) treated with EO4010 + nivolumab (EO/N).

Journal of Clinical Oncology2025-05-28